Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.
ACTH
corticotroph tumor
temozolomide
tumor transformation
vasculature
β-Catenin
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
02
2022
accepted:
19
04
2022
entrez:
5
8
2022
pubmed:
6
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
Clinically silent corticotroph tumors are usually macroadenomas that comprise 20% of ACTH tumors. They frequently progress to aggressive tumors with high recurrence, invasiveness, and on rare occasions, they may become hormonally active causing Cushing's disease. Trustable biomarkers that can predict their aggressive course, as well as their response to traditional or new therapies, are paramount. Aberrant β-Catenin expression and localization have been proposed as responsible for several malignancies including pituitary tumors. Nevertheless, the role of β-Catenin in the aggressive transformation of silent corticotropinomas and their response to Temozolomide salvage treatment have not been explored yet. In this work, we present a case of a silent corticotroph tumor that invaded cavernous sinus and compressed optic chiasm and, after a first total resection and tumor remission it recurred six years later as an aggressive ACTH-secreting tumor. This lesion grew with carotid compromise and caused Cushing's signs. It required multiple medical treatments including Cabergoline, Ketoconazole, TMZ, and radiotherapy. Besides, other two surgeries were needed until it could be controlled. Interestingly, we found α-SMA vascular area reduction and differential β-Catenin cell localization in the more aggressive tumor stages characterized by high Ki-67 indexes and p53 expression. Our results may indicate a role of angiogenesis and β-Catenin trigged events in the pituitary tumor progression, which could in turn affect the response to TMZ and/or conventional treatments. These molecular findings in this unusual case could be useful for future management of aggressive pituitary tumors.
Identifiants
pubmed: 35928898
doi: 10.3389/fendo.2022.870172
pmc: PMC9344046
doi:
Substances chimiques
beta Catenin
0
Adrenocorticotropic Hormone
9002-60-2
Temozolomide
YF1K15M17Y
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
870172Informations de copyright
Copyright © 2022 Demarchi, Perrone, Esper Romero, De Bonis, Casasco, Sevlever, Berner and Cristina.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Endocrinology. 2005 Jul;146(7):2952-62
pubmed: 15817666
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11303-4
pubmed: 21719710
Cancer. 2001 Jan 1;91(1):42-8
pubmed: 11148558
Pituitary. 2015 Apr;18(2):225-31
pubmed: 25534889
Endocr Pathol. 2012 Jun;23(2):123-31
pubmed: 22327960
Front Neurol. 2021 Jun 18;12:700007
pubmed: 34220696
Int J Mol Sci. 2020 Apr 18;21(8):
pubmed: 32325698
Pituitary. 2016 Aug;19(4):415-21
pubmed: 27106209
Pituitary. 2012 Mar;15(1):37-43
pubmed: 21858654
Endocr Pathol. 2010 Sep;21(3):154-60
pubmed: 20473646
Front Endocrinol (Lausanne). 2018 Nov 30;9:706
pubmed: 30555413
J Neurooncol. 2005 Jun;73(2):131-4
pubmed: 15981102
Neurosurgery. 2012 Feb;70(2):491-6; discussion 496
pubmed: 21822153
Pituitary. 2018 Apr;21(2):183-193
pubmed: 29344907
Nat Commun. 2015 Nov 25;6:8904
pubmed: 26603103
Hormones (Athens). 2007 Jul-Sep;6(3):227-32
pubmed: 17724007
Asian J Neurosurg. 2020 May 29;15(2):385-390
pubmed: 32656137
Endocrinology. 2008 Mar;149(3):1235-42
pubmed: 18079202
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188356
pubmed: 32147542
Neurosurgery. 2000 Sep;47(3):723-9; discussion 729-30
pubmed: 10981760
J Ovarian Res. 2019 Dec 11;12(1):122
pubmed: 31829231
Tumour Biol. 2022;44(1):85-105
pubmed: 35811548
Neural Regen Res. 2012 Feb 5;7(4):283-9
pubmed: 25806070
EMBO J. 2014 Jul 1;33(13):1454-73
pubmed: 24825347
Cell Signal. 2008 Oct;20(10):1697-704
pubmed: 18555664
J Neurooncol. 2015 Mar;122(1):189-96
pubmed: 25555563
Histopathology. 2007 Mar;50(4):453-64
pubmed: 17448021
Hormones (Athens). 2011 Apr-Jun;10(2):162-7
pubmed: 21724542
J Clin Endocrinol Metab. 1988 Jun;66(6):1111-8
pubmed: 3372677
Br J Neurosurg. 2005 Feb;19(1):38-42
pubmed: 16147581
Int J Endocrinol. 2014;2014:608497
pubmed: 25505910
Int J Endocrinol. 2014;2014:989574
pubmed: 25431591
Pituitary. 2013 Sep;16(3):303-10
pubmed: 22886682
Cancers (Basel). 2020 Oct 14;12(10):
pubmed: 33066652
Pituitary. 2009;12(3):245-55
pubmed: 18946739
Front Endocrinol (Lausanne). 2020 Nov 18;11:576027
pubmed: 33312158
J Endocrinol Invest. 2003 Jan;26(1):23-8
pubmed: 12602530
Int J Oncol. 2018 Jun;52(6):1934-1946
pubmed: 29620167
PLoS One. 2009;4(2):e4580
pubmed: 19238201
Endocr Pathol. 2009 Spring;20(1):35-40
pubmed: 19172414
J Cell Sci. 2011 Feb 15;124(Pt 4):540-7
pubmed: 21245194
Biochem J. 2013 Feb 15;450(1):9-21
pubmed: 23343194
Turk Neurosurg. 2017 May 07;:
pubmed: 28608351
Int J Oncol. 2015 Apr;46(4):1643-50
pubmed: 25646597
Acta Neurochir (Wien). 2012 Aug;154(8):1493-8
pubmed: 22619024
Eur J Endocrinol. 2010 Jul;163(1):35-43
pubmed: 20385723
Endocr Pathol. 1999 Autumn;10(3):229-235
pubmed: 12114703
Eur J Endocrinol. 2018 Mar;178(3):265-276
pubmed: 29330228
Turk Neurosurg. 2014;24(6):963-6
pubmed: 25448217
EMBO J. 2012 Jun 13;31(12):2737-46
pubmed: 22617421
Endocrine. 2020 Dec;70(3):593-606
pubmed: 32946040
Biomed Res Int. 2016;2016:5378567
pubmed: 27529071
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):903-10
pubmed: 25216855
Endocrinol Diabetes Metab Case Rep. 2019 Oct 01;2019:
pubmed: 31671410
Cancer Res. 2003 Jun 15;63(12):3145-53
pubmed: 12810642
Semin Ophthalmol. 2009 May-Jun;24(3):185-9
pubmed: 19437356
Sci Rep. 2018 May 9;8(1):7329
pubmed: 29743726
Cell. 2017 Jun 1;169(6):985-999
pubmed: 28575679
Int J Mol Sci. 2020 Oct 22;21(21):
pubmed: 33105836